Početna stranicaBMY • NYSE
add
Bristol-Myers Squibb Co
54,32 $
Poslije radnog vremena:(0,037 %)+0,020
54,34 $
Zatvoreno: 1. stu, 18:40:40 GMT -5 · USD · NYSE · Odricanje od odgovornosti
Preth. zaklj. cijena
55,77 $
Dnevni raspon
54,20 $ - 55,90 $
Godišnji raspon
39,35 $ - 56,20 $
Tržišna kapitalizacija
110,13 mlr. USD
Prosječna količina
11,57 mil.
P/E omjer
-
Prinos dividende
4,42 %
Glavno tržište vrijednosnica
NYSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 11,89 mlr. | 8,44 % |
Operativni troškovi | 6,74 mlr. | 5,70 % |
Neto dohodak | 1,21 mlr. | −37,19 % |
Neto profitabilnost | 10,18 | −42,09 % |
Zarada po dionici | 1,80 | −10,00 % |
EBITDA | 4,92 mlr. | 8,12 % |
Efektivna porezna stopa | 27,51 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 6,65 mlr. | −13,43 % |
Ukupna imovina | — | — |
Ukupne obveze | — | — |
Ukupni kapital | 17,07 mlr. | — |
Dionice u optjecaju | 2,03 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 6,65 | — |
Povrat imovine | — | — |
Povrat kapitala | 8,09 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 1,21 mlr. | −37,19 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut. Wikipedia
Glavni izvršni direktor
Osnovano
1887
Web-lokacija
Zaposlenici
34.100
